• Corpus ID: 19472780

Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.

  title={Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.},
  author={Clive S. Woodhouse and Jr. Alton Charles Morgan},
  journal={Cancer research},
  volume={49 10},
Murine monoclonal antibodies have been developed against human colorectal tumors using immunogens consisting of extracts from xenografted human colon carcinoma bound to lectin-conjugated agarose beads. Antibodies of the IgG3 isotype were selected from the resulting fusions, since we and other investigators have reported that this class of antibody can mediate antibody-dependent cellular cytotoxicity (ADCC). They were characterized with respect to specificity, ADCC activity, and complement… 
Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Peripheral blood mononuclear cells obtained from normal donors as well as from cancer patients were able to interact with Lym-1 to elicit ADCC, which was higher than normal individuals and which were further augmented by in vitro incubation with rIL-2.
Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages.
The data suggest that either low-affinity Fc receptor is capable of functioning independently to mediate phagocytosis of tumor cells, and suggest that in vivo applicability of this efficient form of cytotoxicity is potentially important.
Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.
The D612 antigen was shown to be clearly distinct from previously described gastrointestinal carcinoma-associated glycoproteins, and shows a migration pattern of SDS-PAGE distinct from those of the antigens recognized by MAbs KS1/4 and GA733, and reciprocal immunodepletion analyses of D-[3H]glucosamine-labeled colon carcinoma cells utilizing MAbs D612 andGA733 revealed no cross-reactivity between these antibodies.
Tumor‐cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small‐cell lung carcinoma
The results demonstrate that Fuc‐GMI can act as a target antigen on tumor cells for specific immunotherapy in vitro and in a mouse model in vivo and suggest that humoral and cellular effectors may co‐operate in specific tumoricidal reactions and that these may be induced by antibodies of both IgG and IgM isotypes.
Lymphokine‐activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612
The specificity and ADCC properties of the D612 MAb suggest that it should be considered as a candidate for immunotherapy of colon cancer, particularly when used in combination with IL‐2 plus LAK cell treatment.
Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity1
Cell surface reactivity is compared using flow cytometry assays (FACS), complement-fixing ability, and CDC activity of a panel of mAbs and immune sera from clinical trials on the same two tumor cell lines to identify a factor which may contribute to resistance from CDC against cancer cells.
Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor
Evidence is presented that phagocytosis of intact target cells is the principal mechanism of antitumor cytotoxicity in the authors' in vitro model of ADCC by cultured monocytes, and that preventing the release of radioisotope tracers thus prevents the detection of this very efficient form of cytot toxicity by most conventional assays.
Monoclonal antibody therapy.
Monoclonal antibodies were the first successful targeted anti-cancer therapeutics in the modern era. In the 1970s elucidation of hybridoma and molecular biology technologies established mechanisms to
Lymphokines and cytokines as cancer treatment.Immunotherapy realized
Lymphokines, cytokines, and monoclonal antibodies, all products of biotechnology, have resulted in fulfillment of the promise of the immune system for inhibition of growth of human malignancy.